Amlodipine/telmisartan - Boehringer Ingelheim

Alternative Names: Amlodipine besylate/telmisartan; Micamlo Combination Tablets; Micardis Amlo; Micardis Anlo; Onduarp; Telmisartan/amlodipine; Telmisartan/amlodipine besylate; Twynsta

Latest Information Update: 24 Mar 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Boehringer Ingelheim
Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines
Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Hypertension

Most Recent Events

18 Dec 2017 Chemical structure information added
07 Jan 2016 Boehringer Ingelheim and Astellas Pharma extend agreement related to sale and co-promotion of telmisartan/amlodipine for Hypertension in Japan
29 Oct 2013 Boehringer Ingelheim plans a phase III trial for Hypertension (combination therapy) in Japan (NCT01975246)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.